176 related articles for article (PubMed ID: 18065407)
1. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
[TBL] [Abstract][Full Text] [Related]
2. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Trümper L; Zwick C; Ziepert M; Hohloch K; Schmits R; Mohren M; Liersch R; Bentz M; Graeven U; Wruck U; Hoffmann M; Metzner B; Hasenclever D; Loeffler M; Pfreundschuh M;
Ann Oncol; 2008 Mar; 19(3):538-44. PubMed ID: 18212092
[TBL] [Abstract][Full Text] [Related]
4. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
[TBL] [Abstract][Full Text] [Related]
5. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
8. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
11. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N; Zeynalova S; Glass B; Kaiser U; Cavallin-Stahl E; Wolf M; Haenel M; Loeffler M; Truemper L; Pfreundschuh M
Ann Oncol; 2012 May; 23(5):1267-1273. PubMed ID: 21989328
[TBL] [Abstract][Full Text] [Related]
12. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rudolph C; Reiser M; Hossfeld DK; Metzner B; Hasenclever D; Schmitz N; Glass B; Rübe C; Loeffler M;
Blood; 2004 Aug; 104(3):626-33. PubMed ID: 14982884
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
16. Sequential versus alternating chemotherapy for high grade non-Hodgkin's lymphomas: a randomized multicentre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Steinhauer EU; Gropp C; Oehl S; Lötzke E
Hematol Oncol; 1991; 9(4-5):217-23. PubMed ID: 1743624
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
19. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
[TBL] [Abstract][Full Text] [Related]
20. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]